Published in Am Rev Respir Dis on September 01, 1991
Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol (2001) 1.96
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol (1997) 1.47
Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev (2010) 1.39
Enhanced surfactant protein and defensin mRNA levels and reduced viral replication during parainfluenza virus type 3 pneumonia in neonatal lambs. Clin Diagn Lab Immunol (2004) 1.25
High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax (1992) 1.23
Role of semaphorin 7a signaling in transforming growth factor β1-induced lung fibrosis and scleroderma-related interstitial lung disease. Arthritis Rheum (2011) 1.14
Asbestos-induced peribronchiolar cell proliferation and cytokine production are attenuated in lungs of protein kinase C-delta knockout mice. Am J Pathol (2007) 1.10
Immunotherapy of systemic sclerosis. Immunotherapy (2010) 1.03
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis (2001) 1.02
New perspectives on basic mechanisms in lung disease. 1. Lung injury, inflammatory mediators, and fibroblast activation in fibrosing alveolitis. Thorax (1992) 1.01
Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin Rheumatol (2006) 0.95
Exhaled nitric oxide as a biomarker in COPD and related comorbidities. Biomed Res Int (2014) 0.94
Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-β1 signaling. J Immunol (2012) 0.94
Interstitial lung disease in systemic sclerosis. Lung (2007) 0.94
The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration. Am J Respir Cell Mol Biol (2009) 0.93
Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis (1999) 0.92
Interstitial lung disease in scleroderma. Rheum Dis Clin North Am (2015) 0.88
On the respiratory mechanics measured by forced oscillation technique in patients with systemic sclerosis. PLoS One (2013) 0.88
Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma. J Cell Mol Med (2013) 0.85
B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol (2011) 0.82
MicroRNAs as potential targets for progressive pulmonary fibrosis. Front Pharmacol (2015) 0.81
In search of a cause of cryptogenic fibrosing alveolitis (CFA): one initiating factor or many? Thorax (1998) 0.80
Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement. Clin Rheumatol (2012) 0.80
Cryptogenic fibrosing alveolitis and the fibrosing alveolitis of systemic sclerosis: morphological differences on computed tomographic scans. Thorax (1997) 0.79
A syndrome resembling human systemic sclerosis (scleroderma) in MRL/lpr mice lacking interferon-gamma (IFN-gamma) receptor (MRL/lprgammaR-/-). Clin Exp Immunol (1999) 0.79
HLA markers for poor prognosis in systemic sclerosis Brazilian patients. Dis Markers (2013) 0.77
Circulating biomarkers of interstitial lung disease in systemic sclerosis. Int J Rheumatol (2012) 0.77
Challenges and opportunities in treating inflammation associated with pulmonary hypertension. Expert Rev Cardiovasc Ther (2016) 0.76
Imbalance of pro- and anti-inflammatory cytokines in pulmonary sarcoidosis. Mediators Inflamm (1996) 0.75
Clinical, laboratory and radiological findings in pulmonary fibrosis with and without connective tissue disease. Clin Rheumatol (1997) 0.75
Follicular bronchiolitis, an unusual cause of haemoptysis in giant cell arteritis. Clin Rheumatol (2005) 0.75
The new World Health Organization classification of lung tumours. Eur Respir J (2001) 6.91
On observing patterns of airflow obstruction in chronic asthma. Br J Dis Chest (1977) 6.54
Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol (2001) 5.67
Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax (1980) 3.70
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) (2004) 3.12
Evaluation of polymerase chain reaction for diagnosis of pneumococcal pneumonia. J Clin Microbiol (1993) 3.04
Oat-cell carcinoma of the lung. Its origin and relationship to bronchial carcinoid. Cancer (1968) 2.94
Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J (Clin Res Ed) (1983) 2.86
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
Progressive airway obliteration in adults and its association with rheumatoid disease. Q J Med (1977) 2.83
Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? J Rheumatol (1994) 2.76
Antibodies in some chronic fibrosing lung diseases. I. Non organ-specific autoantibodies. Clin Allergy (1971) 2.71
Circulating rheumatoid and antinuclear factors in asbestos workers. Br Med J (1970) 2.67
The specificity of fetal IgM: antibody or anti-antibody? Ann N Y Acad Sci (1975) 2.65
Nocturnal asthma: a study in general practice. J R Coll Gen Pract (1989) 2.55
Phagocytic function of polymorphonuclear leukocytes in rheumatic diseases. J Clin Invest (1973) 2.51
Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus. J Immunol (1976) 2.49
A survey of prelicensure pain curricula in health science faculties in Canadian universities. Pain Res Manag (2009) 2.49
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
Pulmonary lymphangiomyomatosis. A review. Am J Pathol (1975) 2.46
The promise of integrated representative surveys about sexually transmitted diseases and behavior. Sex Transm Dis (1997) 2.44
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun (1993) 2.32
Cryptogenic fibrosing alveolitis and lung cancer. Thorax (1980) 2.31
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
Bronchoalveolar lavage in pulmonary fibrosis: comparison of cells obtained with lung biopsy and clinical features. Thorax (1980) 2.28
Nocturnal and morning asthma. Relationship to plasma corticosteroids and response to cortisol infusion. Thorax (1975) 2.28
Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax (1980) 2.27
Evaluation of bias in diagnostic-test sensitivity and specificity estimates computed by discrepant analysis. J Clin Microbiol (1998) 2.14
Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM (2007) 2.14
Role of superoxide dismutase and catalase as determinants of pathogenicity of Nocardia asteroides: importance in resistance to microbicidal activities of human polymorphonuclear neutrophils. Infect Immun (1985) 2.06
Evaluation of nucleic acid amplification tests as reference tests for Chlamydia trachomatis infections in asymptomatic men. J Clin Microbiol (2000) 2.02
Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol (1997) 2.00
Experimental paraquat poisoning: a histological and electron-optical study of the changes in the lung. J Pathol (1971) 1.96
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) (2006) 1.94
Fibrosing alveolitis and chronic liver disease. Q J Med (1968) 1.91
Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis (2000) 1.89
Interaction of Pseudomonas aeruginosa with human respiratory mucosa in vitro. Eur Respir J (1994) 1.87
Epithelial-myoepithelial carcinomas of the bronchus. Am J Surg Pathol (2001) 1.85
Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum (1996) 1.85
Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) (2008) 1.83
Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol (1988) 1.83
Comparison of arbitrarily primed polymerase chain reaction, ribotyping, and monoclonal antibody analysis for subtyping Legionella pneumophila serogroup 1. J Clin Microbiol (1993) 1.82
Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax (1980) 1.82
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) (2001) 1.82
Association of HLA B8 with spontaneous resolution in sarcoidosis. Thorax (1981) 1.80
A pilot study of the prevalence of chlamydial infection in a national household survey. Sex Transm Dis (1998) 1.78
Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis (1981) 1.76
Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet (1991) 1.76
Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet (1991) 1.76
Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax (1989) 1.75
Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem (2000) 1.74
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
Correlation between fibre content of the lung and disease in east London asbestos factory workers. Br J Ind Med (1988) 1.72
Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med (1990) 1.71
alpha 1-antitrypsin phenotypes in fibrosing alveolitis and rheumatoid arthritis. Lancet (1977) 1.70
Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed) (1984) 1.68
Nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis (1975) 1.67
Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. Hybridoma (1984) 1.67
Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol (1998) 1.66
Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) (2001) 1.66
The source and role of RANTES in interstitial lung disease. Eur Respir J (1997) 1.62
Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein gene (omp1). Sex Transm Infect (2001) 1.62
Histogenesis of the so-called "intravascular bronchioloalveolar tumour". J Pathol (1979) 1.61
An anti-platelet-endothelial cell adhesion molecule-1 antibody inhibits leukocyte extravasation from mesenteric microvessels in vivo by blocking the passage through the basement membrane. J Exp Med (1996) 1.58
Subclinical liver disease in systemic lupus erythematosus. J Rheumatol (1982) 1.57
Silicosis in a Himalayan village population: role of environmental dust. Thorax (1991) 1.57
Pulmonary haemosiderosis and pulmonary haemorrhage. Br J Dis Chest (1981) 1.56
Inflammation in cystic fibrosis airways: relationship to increased bacterial adherence. Eur Respir J (2001) 1.55
Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis (1983) 1.55
Lung tumours and ACTH production. Clin Endocrinol (Oxf) (1977) 1.54
Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology (1994) 1.54
The use of infra-red thermography in a rheumatology unit. Br J Rheumatol (1990) 1.53
Unusual sclerosing haemangiomas and sclerosing haemangioma-like lesions, and the value of TTF-1 in making the diagnosis. Histopathology (2002) 1.53
Aspergillus fumigatus and lung disease. Postgrad Med J (1979) 1.52
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
Mesenchymoma of the lung (so called hamartoma): a review of 154 parenchymal and endobronchial cases. Thorax (1987) 1.51
High prevalence of antinuclear antibodies in sandblasters' silicosis. Am Rev Respir Dis (1976) 1.51
Chronic bronchial suppuration and inflammatory bowel disease. Q J Med (1981) 1.50
Lymphocyte responses to phytohaemagglutinin in patients with asbestosis and pleural mesothelioma. Clin Exp Immunol (1978) 1.50
Anaerobic subareolar breast abscess. Lancet (1979) 1.49
Cryptogenic fibrosing alveolitis: assessment by graded trephine lung biopsy histology compared with clinical, radiographic, and physiological features. Br J Dis Chest (1981) 1.49
Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med (1994) 1.49
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol (1997) 1.47
Antibodies in some chronic fibrosing lung diseases. II. Immunofluorescent studies. Clin Allergy (1971) 1.47
Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use-effectiveness study in public health settings. Sex Transm Dis (1998) 1.46
Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum (1999) 1.45
Evidence in man of synergistic interaction between putative mediators of acute inflammation and asthma. Lancet (1982) 1.45
Progress in systemic sclerosis: a 10-year perspective. Rheumatology (Oxford) (2009) 1.44
Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis. Eur Respir J (1999) 1.44
Circulating immune complexes in patients with cryptogenic fibrosing alveolitis. Clin Exp Immunol (1979) 1.44
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax (1997) 1.43
The British Thoracic Society. Thorax (1982) 1.42